shortsqueeze

-Strong base formed(blue lines) -There are still many uncovered shorts, another round of short squeeze incoming. -Price is above 200EMA, looking to long than to short.

TOO MUCH BAD NEWS IN THE PRICE? All it took was a positive comment from the Pacific Crest analyst yesterday, about the upcoming earnings and the prospects for Karma, to take the stock 10% up in 3x average volume. Short interest has been so high on GPRO and the stock has been so neglected in the recent rally that any marginally positive presumption (not even news) ...

STRP is a low float stock (5.82m shares) with a high "short float" of 46.93%. The higher it goes, the more shorts get squeezed and cover their short position, pushing price action even higher. Stock is up 30% / week and formed 2/3 leg of evening star reversal. Will consider long position about 36.75 or short position below 34.40. Will shorts get squeezed today or ...

GSM is an interesting stock, with almost 70% short float and up 30% for the month. It's had several unprofitable quarters, but yet still pays 8 cent dividends. It certainly got a lift because of the president-elect Trumps plans to build/repair the nations infrastructure, bridges, etc.

So, centerline is reached. Me personally expecting a hell of a short squeeze and new highs in a couple days... P!

...then shorts getting bagged very quick. P!

With Array Biopharma earnings this week, the chance of another short squeeze increases, but so does your risk. Golden Cross on Daily, positive divergence on MACD, riding the upper Bollinger Band as of 8/2. My $ARRY upside target is $5.47 NASDAQ:ARRY

This stock looks pretty nice for a long swing if we break 16.20, the stock have more than 34% of short interest, if we break that level we should move fast becaouse a lot of people put their stop into tha area

$ATRS not my typical play but recent insiders and fairly high short interest Settlement Date Short Interest Avg Daily Share Volume Days To Cover 3/15/2016 10,444,826 866,786 12.050063

In this chart I illustrate the different facets of the trend in the Euro. It's clear to me that we're about to witness a large short squeeze rally, as evidenced by the following technical landmarks: Rgmov is moving up in the weekly and daily, not validating the recent decline (which also happened during very low liquidity sessions) There's a potential time at ...

Start of a long term, high profit trend. Has continued short interest in the face of reg-sho forced buybacks (buy-ins), brokers are forcing people to cover at a loss and now have the stock on not able to borrow lists. At historically low levels with support and high bullish volume. Reward to risk favors the longs, a wise portfolio investment.

Looks like the market is about to get squeezed down below the breakout zone. It will probably stop anywhere from $200 to $210 next. We have a large downward channel acting as the top of a descending triangle that will take us to the low $200s. We had a failed H&S that took us to $245 where we were stopped by the lower end of the breakout zone before the big ...

40% short interest 30+ days to cover, and several buy signals shaping up. Bullish MACD Cross, Stochastics, and breaking out of a steep downtrend. New 3 month closing highs after retaking both the 50 day and 200 day moving averages this week. Weekly PAR SAR just printed bullish as well. Would jump in or add on the break of $7.50. On a fundamental basis they ...

For detailed commentary and analysis, see our blog post published 10/3/14: http://www.syncubate.com/blog/2014/10/2/gopro-goes-berserk In this post, we'll dissect the stock's surreal run up from the low $50s in the beginning of September to its near-term high of $96.45 on 9/30/14. Our chart as published on our blog represents two time frames of interest to us ...

Continuing coverage of ACRX this week, we saw ACRX pullback with the market as a whole early this morning. ACRX broke right through support at the .236 retrace, but found support at yesterdays congested zone at the .382 retrace. Uptrend remains in place. $9 remains 1st target. Stop now at 7.70.

Posted a chart on ACRX earlier in the day as a possible short squeeze. ACRX rallied 4% since the posting. Please refer to my earlier chart for analysis.

After getting hammered in July from the FDA delaying approval on its' latest drug for pain relief, Bears have been piling on making an incredible 20% of the float short. Recent buy ratings from analysts could be the catalyst to get a short squeeze going to begin filling the gap left from the huge 40%+ drop in July. If momentum can carry the stock past 8, then 9 ...